Nils Ternès

3.6k total citations
24 papers, 545 citations indexed

About

Nils Ternès is a scholar working on Molecular Biology, Statistics and Probability and Oncology. According to data from OpenAlex, Nils Ternès has authored 24 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Statistics and Probability and 8 papers in Oncology. Recurrent topics in Nils Ternès's work include Statistical Methods and Inference (6 papers), Statistical Methods in Clinical Trials (6 papers) and Gene expression and cancer classification (6 papers). Nils Ternès is often cited by papers focused on Statistical Methods and Inference (6 papers), Statistical Methods in Clinical Trials (6 papers) and Gene expression and cancer classification (6 papers). Nils Ternès collaborates with scholars based in France, United States and Czechia. Nils Ternès's co-authors include Stefan Michiels, Federico Rotolo, Chiara Colombo, Sylvie Bonvalot, Marco Fiore, Federica Perrone, Axel Le Cesne, Ariane Dunant, Andrea Marrari and Charles Honoré and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Bioinformatics.

In The Last Decade

Nils Ternès

23 papers receiving 542 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nils Ternès France 10 254 182 156 103 89 24 545
Mary Lou Keohan United States 12 672 2.6× 98 0.5× 492 3.2× 138 1.3× 114 1.3× 22 923
Peter W. Gieser United States 9 284 1.1× 92 0.5× 178 1.1× 191 1.9× 39 0.4× 9 560
Yu‐Nien Sun United States 13 129 0.5× 155 0.9× 206 1.3× 46 0.4× 298 3.3× 30 702
Phataraporn Thorson United States 10 380 1.5× 178 1.0× 81 0.5× 35 0.3× 153 1.7× 13 547
M Bodó Hungary 10 179 0.7× 77 0.4× 133 0.9× 76 0.7× 40 0.4× 32 498
Jui Lan Taiwan 17 385 1.5× 294 1.6× 226 1.4× 115 1.1× 233 2.6× 42 912
I Weng Lao China 15 294 1.2× 193 1.1× 191 1.2× 83 0.8× 123 1.4× 34 597
Franchette W.P.J. van den Berkmortel Netherlands 16 169 0.7× 35 0.2× 388 2.5× 50 0.5× 142 1.6× 58 771
Christophe Zemmour France 13 141 0.6× 32 0.2× 247 1.6× 36 0.3× 147 1.7× 51 575
Andrew T. Turk United States 15 153 0.6× 45 0.2× 168 1.1× 63 0.6× 160 1.8× 39 650

Countries citing papers authored by Nils Ternès

Since Specialization
Citations

This map shows the geographic impact of Nils Ternès's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nils Ternès with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nils Ternès more than expected).

Fields of papers citing papers by Nils Ternès

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nils Ternès. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nils Ternès. The network helps show where Nils Ternès may publish in the future.

Co-authorship network of co-authors of Nils Ternès

This figure shows the co-authorship network connecting the top 25 collaborators of Nils Ternès. A scholar is included among the top collaborators of Nils Ternès based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nils Ternès. Nils Ternès is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gazzah, Anas, Nils Ternès, Joon Sang Lee, et al.. (2025). Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer. Translational Oncology. 63. 102615–102615.
2.
Ternès, Nils, et al.. (2025). Variable Selection in High-Dimensional Logistic Regression Models Using a Whitening Approach. PubMed. 22(2). 800–807. 1 indexed citations
3.
Lévy‐Leduc, Céline, et al.. (2023). Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso. BMC Bioinformatics. 24(1). 25–25. 3 indexed citations
4.
Lefebvre, Anne‐Marie, Julien Adam, Céline Nicolazzi, et al.. (2023). The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape. Lung Cancer. 184. 107356–107356. 9 indexed citations
5.
Vincenti, Flavio, Oriol Bestard, Josep M. Cruzado, et al.. (2023). Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant. Journal of the American Society of Nephrology. 35(3). 347–360. 14 indexed citations
6.
7.
Lin, Nan, Amy Damask, Anita Boyapati, et al.. (2022). UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab. The Pharmacogenomics Journal. 22(3). 160–165. 2 indexed citations
8.
Bardia, Aditya, Sarat Chandarlapaty, Hannah M. Linden, et al.. (2022). AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nature Communications. 13(1). 4116–4116. 40 indexed citations
9.
10.
11.
Lévy‐Leduc, Céline, et al.. (2021). A variable selection approach for highly correlated predictors in high-dimensional genomic data. Bioinformatics. 37(16). 2238–2244. 6 indexed citations
12.
Chandarlapaty, Sarat, Aditya Bardia, Simon Lord, et al.. (2020). 277MO SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study. Annals of Oncology. 31. S351–S351. 3 indexed citations
13.
Moalla, Salma, Julia Arfi‐Rouche, Stéphanie Foulon, et al.. (2017). Are we reproducible in measurement of NET liver metastasis?. Digestive and Liver Disease. 49(10). 1121–1127. 4 indexed citations
14.
Ternès, Nils, Federico Rotolo, & Stefan Michiels. (2017). biospear: an R package for biomarker selection in penalized Cox regression. Bioinformatics. 34(1). 112–113. 13 indexed citations
15.
Ternès, Nils, Federico Rotolo, & Stefan Michiels. (2017). Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials. BMC Medical Research Methodology. 17(1). 83–83. 6 indexed citations
16.
Michiels, Stefan, Nils Ternès, & Federico Rotolo. (2016). Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. Annals of Oncology. 27(12). 2160–2167. 28 indexed citations
17.
Schuster, Tibor, et al.. (2015). Contour plot assessment of existing meta-analyses confirms robust association of statin use and acute kidney injury risk. Journal of Clinical Epidemiology. 68(10). 1138–1143. 6 indexed citations
18.
Deschamps, Frédèric, Geoffroy Farouil, Nils Ternès, et al.. (2014). Thermal ablation techniques: a curative treatment of bone metastases in selected patients?. European Radiology. 24(8). 1971–1980. 97 indexed citations
19.
Ternès, Nils, Mónica Arnedos, Serge Koscielny, Stefan Michiels, & Émilie Lanoy. (2014). Statistical methods applied to omics data. Current Opinion in Oncology. 26(6). 576–583. 4 indexed citations
20.
Bonvalot, Sylvie, Nils Ternès, Marco Fiore, et al.. (2013). Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought. Annals of Surgical Oncology. 20(13). 4096–4102. 162 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary Lou Keohan Breakdown of academic impact, for papers by Peter W. Gieser Breakdown of academic impact, for papers by Yu‐Nien Sun Breakdown of academic impact, for papers by Phataraporn Thorson Breakdown of academic impact, for papers by M Bodó Breakdown of academic impact, for papers by Jui Lan Breakdown of academic impact, for papers by I Weng Lao Breakdown of academic impact, for papers by Franchette W.P.J. van den Berkmortel Breakdown of academic impact, for papers by Christophe Zemmour Breakdown of academic impact, for papers by Andrew T. Turk
Rankless by CCL
2026